Navigation Links
WHO data confirms low level of resistance to Tamiflu

seltamivir- in advance is presently the only way to ensure that sufficient supplies are available in the event of a pandemic. Roche has been working closely with WHO and national governments to ensure governments are aware of the importance of stockpiling antivirals in the event of a pandemic situation. Roche has received and fulfilled pandemic orders for Tamiflu from more than 80 countries worldwide. The magnitude of these orders varies with some countries, France, Finland, Iceland, Ireland, Luxembourg, Netherlands, New Zealand, Norway, Switzerland and UK stockpiling or intending to stockpile adequate quantities of Tamiflu to cover 20-40% of their population. Roche has also donated 5.125 million courses of Tamiflu treatment to the WHO for international rapid response and regional response to a pandemic influenza strain.

About influenza

Influenza, commonly called the ‘flu? is a serious disease and annual outbreaks and epidemics are caused by influenza A and B viruses. Influenza is a highly contagious viral illness and is characterised by a sudden onset of debilitating clinical symptoms which affect the entire body. Up to 500 million people are infected by influenza and up to 500,000 deaths are attributed to influenza each year. Influenza complications occur in all patient groups and include bronchitis, sinusitis, otitis media, and pneumonia.

About Tamiflu

Tamiflu is designed to be active against all clinically relevant influenza viruses and works by blocking the action of the neuraminidase (NA) enzyme on the surface of the virus. When neuraminidase is inhibited, the virus is not able to spread to and infect other cells in the body.

It is licensed for the treatment and prophylaxis of influenza in children aged one year and above and in adults.
'"/>

Source:Ketchum


Page: 1 2 3

Related biology news :

1. LUCA technologies confirms real-time methane generation
2. Ancient DNA confirms single origin of Malagasy primates
3. Updated data on novel HPV vaccine confirms efficacy in large population
4. First human study confirms that immune cells can be a primary cause of bone loss in gum disease
5. New method confirms importance of fungi in Arctic nitrogen cycle
6. New data from NIH lab confirms protocol to reverse type 1 diabetes in mice
7. Genetic surprise confirms neglected 70-year-old evolutionary hypothesis
8. Re-analysis of cigarettes confirms tobacco companies increased addictive nicotine 11 percent
9. Cornell lab confirms deadly fish virus spreading to new species
10. Unprecedented water level rise in Somalia
11. Low level of extinction during ice age linked to adaptability

Post Your Comments:
(Date:11/23/2009)...niversity of Alabama at Birmingham (UAB) researche...g medical conditions (co-morbidity) do not explain...ricans compared to Caucasians who also have colon ...Cancer , a journal of the American Cancer Society....o-morbidity are independent predictors of poor sur...
(Date:11/23/2009)...l in unprecedented detail how the ribosome interac...nd guide them toward their destination in biologic...ible fitting (MDFF) to examine the interaction of .... , The first study, in Proceedings of the Nat...signaling between the ribosome and an elongation f...
(Date:11/23/2009)...scoveries about the multiple health benefits of vi... nutrient, increased awareness of the huge numbers...ch and even led to an appreciation of it as "natur...alth of your immune system to prevention of heart ...in D is now seen as one of the most critical nutri...
Breaking Biology News(10 mins):Racial disparity in colon cancer survival not easily explained, UAB researchers say 2Computational microscope peers into the working ribosome 2Computational microscope peers into the working ribosome 3Multiple health concerns surface as winter, vitamin D deficiences arrive 2Multiple health concerns surface as winter, vitamin D deficiences arrive 3Helix BioPharma to Present L DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 12711 1Helix BioPharma to Present L DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 12711 2Helix BioPharma to Present L DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 12711 3Helix BioPharma to Present L DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 12711 4Helix BioPharma to Present L DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 12711 5Chemicals in Marijuana Smoke May Harm DNA 49526 1Synutra Annual Report on Form 10 K Includes Going Concern Explanatory Paragraph from Auditor 49524 1Synutra Annual Report on Form 10 K Includes Going Concern Explanatory Paragraph from Auditor 49524 2
... expanding into new territory, successfully aiding...valves in patients too sick to withstand open-ches...th Annual Scientific Sessions of the Society for C..., May 9?2, 2007, in Orlando, FL, patients who were...Valve, Irvine, CA) experienced improvements in bot...
...e use of tissue-engineered scaffolding made of car... naturally, to replace defective cartilage tissue....caffold which is implanted into the body, where ne...he study appears in the journal Artificial Organs....d mice as the study found these scaffolds to be a ...
...e-dose anticlotting medication just before percuta...d risk of heart attack and cardiac death by half, ...cientific Sessions of the Society for Cardiovascul...2007, in Orlando, FL. , Researchers found that gi...e stenting, rather than the standard 300-mg dose, ...
Other Biology News:Percutaneous aortic valve replacement safe, successful in high-risk patients 2High-dose anticlotting drug cuts heart attack, death risk in half 2
(Date:11/20/2009)...ecently announced that Dr. Dominique Hebrault will...s Analytical Technology (PAT) in Green Chemistry a..., (PRWEB) November 20, 200...chnology (PAT) in Green Chemistry and Green Engine...echnology (PAT) case studies will be presented on ...
(Date:11/19/2009)...rstCall/ -- Omeros Corporation (Nasdaq: OMER ) to...third quarter ended September 30, 2009. For the th...ed a net loss of $3.9 million, or $1.34 per share,...54 per share, for the same period in 2008. For the... reported a net loss of $15.5 million, or $5.29 pe...
(Date:11/19/2009)...irstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), ann... to its shareholders, discussing the Company,s acq...euticals Holdings, Inc. (CHBP), an integrated bio-...lic of China. The merger gives NeoStem a controlli...Ltd., CHBP,s primary operating subsidiary and a pr...
(Date:11/19/2009)...er 19 MONITORING FORCE GmbH,announ...ibanserin in the,indication treatment-relevant lev...r orphan drug status designation with the European...sia is a complication of the mainstay,treatment in... of those,affected, since it may be disabling for ...
Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
... 16 ,Boston Scientific Corporation (NYSE: BSX ) a...the signing of a definitive merger agreement, unde... price of $1.35 per share of,CryoCor, or approxima...elopment agreement, in place since June 2007, to p...n, or "Afib." Afib is the most common,cardiac arrh...
... Inc.,announced today that it has closed the secon...cing. As previously announced, Aisling Capital led...ew investors, the D.E. Shaw,group and Boston Life ...omura Phase4 Ventures, Novartis BioVentures, BioFu... Hentsch, BioVeda Fund and Hercules,Technology Gro...
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, ...er and his research group at St. James,s Universit...their work in the April 10 online issue of,Gene Th...Cell Killing by,Oncolytic Reovirus for the Treatme...eovirus effectively kills and replicates,in both h...
Other Biology Technology:Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 2Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 3Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 4Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 5Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement 6Paratek Pharmaceuticals Completes $40 Million Private Placement to Finance Clinical Programs Including Oral Antibiotic to Combat MRSA and Other Infections 2Paratek Pharmaceuticals Completes $40 Million Private Placement to Finance Clinical Programs Including Oral Antibiotic to Combat MRSA and Other Infections 3Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma 2
...RS are multi-functional mixing devices. Stepping m... solid, heavy-duty durable shaker to provide a uni...ature. Regulated action scale for all modes. Micro...trol time, continuous time, action scale and speed...
Finnigan LTQ FT from Thermo Scientific
PDQuest 10-User Network License from Bio-Rad
Mouse Anti-Human JRKL Monoclonal Antibody, Unconjugated, Clone 4E10 from Abnova Corporation
Biology Products: